查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1733384

全球眼科药物和设备市场规模（按产品类型、应用、最终用户、区域范围和预测）

Global Ophthalmology Drugs And Devices Market Size By Product Type (Anti-inflammatory, Anti-glaucoma), By Application (Dry Eye, Eye Allergy), By End-User (Hospitals, Medical Clinics), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格
简介目录

眼科药物及器械市场规模及预测

2024 年眼科药物和设备市场规模价值为 570.2 亿美元，预计到 2032 年将达到 881.8 亿美元，2024 年至 2032 年的复合年增长率为 5.60%。

眼部疾病和病症的盛行率不断上升、人们对眼部疾病的健康意识不断增强、强大的分子管道的存在以及眼科药物和设备的日益普及，极大地推动了全球眼科药物和设备市场的成长。本报告对全球眼科药品和设备市场进行了全面的评估。它对关键细分市场、趋势、市场驱动因素、限制因素、竞争格局以及在市场中发挥关键作用的因素进行了全面的分析。

定义全球眼科药物和设备市场

眼科是专注于眼科疾病的诊断和治疗的医学领域。眼科设备用于各种手术，包括白内障手术、青光眼手术和屈光矫正手术。眼科治疗用于治疗多种眼科疾病，包括感染疾病、青光眼和白内障。由于老年族群中黄斑部病变、老花眼和糖尿病视网膜病变等眼部疾病的发生率和盛行率不断上升，全球眼科药品和设备市场正经历显着增长。随着先进的眼科设备的出现，越来越多的人选择透过眼科手术来治疗眼部疾病。

全球眼科药物和设备市场概况

由于老年族群对治疗黄斑部病变、老花眼、糖尿病视网膜病变等各种眼部疾病的微创手术的需求不断增加，预计未来几年全球眼科药物和设备市场将出现显着增长。眼科疾病和障碍的发病率和盛行率不断增加、人们对眼科疾病和障碍的健康意识不断增强、强大的分子管道的存在以及眼科治疗和设备在某些眼部异常和眼部缺陷的治疗和诊断中的应用日益增多，极大地推动了全球眼科治疗和设备市场的增长。

此外，眼科药物和设备领域的技术进步以及对开发新型眼科药物的研发活动的投资增加也在推动市场成长。此外，全球老龄人口的增长、高血糖导致的眼部疾病的增加、医疗保健领域的增长以及政府以资金和津贴形式为诊断设备和治疗程序提供的倡议和支持不断增加，也推动了眼科药物和设备市场的增长。

此外，预计在预测期内，患有眼部疾病的患者数量不断增加、产品开发和发布活动的活性化、对人工水晶体和超音波设备的巨大需求以及新兴国家的增长潜力将为全球眼科药物和设备市场的相关人员提供丰厚的增长机会。然而，治疗程序成本高、多种药物核准延迟、眼科药物认知度低、熟练医务人员短缺以及专利到期预计将在预测期内阻碍全球眼科药物和设备市场的成长。此外，治疗眼科疾病的风险对眼科药品和设备市场的成长构成了挑战。

目录

第一章全球眼科药品及器材市场简介

  • 市场概览
  • 研究范围
  • 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

  • 资料探勘
  • 验证
  • 第一手资料
  • 资料来源列表

第四章全球眼科药品及器材市场展望

  • 概述
  • 市场动态
    • 驱动程式
    • 限制因素
    • 机会
  • 波特五力模型
  • 价值链分析

第五章全球眼科药品和设备市场（依产品类型）

  • 概述
  • 抗过敏
  • 抗血管内皮生长因子（抗VEGF）药物
  • 抗发炎剂
  • 抗青光眼药物
  • 诊断和监测设备
  • 手术设备
  • 视力保健
  • 其他的

6. 全球眼科药物和设备市场（按应用）

  • 概述
  • 眼睛干涩
  • 眼睛过敏
  • 青光眼
  • 白内障
  • 眼部感染疾病
  • 视网膜疾病
  • 葡萄膜炎
  • 其他的

7. 全球眼科药品和设备市场（按最终用户）

  • 概述
  • 医院
  • 诊所
  • 诊断中心
  • 其他的

8. 全球眼科药品及设备市场（按地区）

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 其他欧洲国家
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 其他亚太地区
  • 其他的
    • 中东和非洲
    • 拉丁美洲

第九章全球眼科药品和设备市场的竞争格局

  • 概述
  • 各公司市场排名
  • 重点发展策略

第十章 公司简介

  • Carl Zeiss AG
  • Novartis AG
  • Johnson And Johnson Services, Inc.
  • Allergan
  • Topcon Corporation
  • Nidek Co., Ltd.
  • HAAG-STREIT GROUP
  • Ziemer Ophthalmic Systems
  • Bausch And Lomb Incorporated, BIoTech
  • VisionCare, Inc.
  • Akorn
  • Incorporated
  • Bayer AG
  • Acucela Inc.
  • Regeneron Pharmaceuticals, Inc
  • Nicox
  • Santen Pharmaceutical Co., Ltd
  • IRIDEX Corporation
  • Alcon Inc

第十一章 公司简介 附录

    • 相关报告
简介目录
Product Code: 69397

Ophthalmology Drugs And Devices Market Size And Forecast

Ophthalmology Drugs And Devices Market size was valued at USD 57.02 Billion in 2024 and is projected to reach USD 88.18 Billion by 2032, growing at a CAGR of 5.60% from 2024 to 2032.

The increasing prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices are driving the growth of the Global Ophthalmology Drugs And Devices Market significantly. The Global Ophthalmology Drugs And Devices Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Ophthalmology Drugs And Devices Market Definition

Ophthalmology is a field of medical science that focuses on the diagnosis and treatment of eye disorders. Ophthalmic devices are used in a variety of procedures such as cataract surgery, glaucoma surgery, and refractive surgery. Ophthalmic drugs are used to treat a wide range of eye diseases, including infection, glaucoma, and cataract. The Global Ophthalmology Drugs And Devices Market is experiencing significant growth because of the rising incidence and prevalence of eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. With the advent of sophisticated ophthalmic devices, people are increasingly going to opt for ophthalmic surgeries to cure their eye-related disorders.

Global Ophthalmology Drugs And Devices Market Overview

The Global Ophthalmology Drugs And Devices Market is expected to experience remarkable growth in the upcoming years owing to the increasing demand for minimally invasive surgeries in the treatment of various eye-related disorders such as macular degeneration, presbyopia, and diabetic retinopathy among the geriatric population. The increasing incidence and prevalence of eye diseases and disorders, rising health awareness among people about the same, presence of a robust pipeline of molecules, and increase in adoption of ophthalmology drugs and devices in the treatment and diagnosis of certain ocular malformations and eye deficits are fueling the growth of Global Ophthalmology Drugs And Devices Market significantly.

Additionally, technological advancement in the field of Ophthalmology Drugs and Devices and increasing investment in R&D activities for the development of new ophthalmological drugs are also promoting market growth. Furthermore, the rise in the geriatric population across the globe, increasing ophthalmic disorders due to high blood sugar, growth in the healthcare sector, and increasing government initiatives and support in the form of funds and grants for diagnostic equipment and treatment procedures, also boost the growth of the Ophthalmology Drugs And Devices Market.

Moreover, an increase in the patient population of eye-related disorders, increasing product development and launch activities, huge demand for intraocular lenses and phacoemulsification devices, and growth potential in developing nations are expected to provide profitable growth opportunities to the market players in the Global Ophthalmology Drugs And Devices Market during the forecast period. However, high cost associated with the treatment procedures, drug approval delays wherein multiple drugs are in the pipeline, low awareness of ophthalmic drugs, lack of skilled healthcare professionals, and patent expiry is expected to hinder the growth of the Global Ophthalmology Drugs And Devices Market over the forecast period. In addition, risks associated with ocular disease treatment are posing challenges to the growth of the Ophthalmology Drugs And Devices Market.

Global Ophthalmology Drugs And Devices Market Segmentation Analysis

The Global Ophthalmology Drugs And Devices Market is Segmented on the basis of Product Type, Application, End-User, and Geography.

Ophthalmology Drugs And Devices Market, By Product Type

  • Anti-allergy
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
  • Anti-inflammatory
  • Anti-glaucoma
  • Diagnostic and Monitoring Devices
  • Surgical Devices
  • Vision Care
  • Others

Based on Product Type, the market is bifurcated into Anti-allergy, Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents, Anti-inflammatory, Anti-glaucoma, Diagnostic and Monitoring Devices, Surgical Devices, Vision Care, and Others. The anti-inflammatory segment accounts for the highest revenue share of the Global market in 2020 and is expected to dominate the market over the forecast period owing to an increase in the prevalence of allergic conjunctivitis and hypersensitivity reactions, as well as an increase in demand for anti-inflammatory drugs in a wide range of conditions such as uveitis, cystoid macular edema, and scleritis. These factors are driving the growth of this segment.

Ophthalmology Drugs And Devices Market, By Application

  • Dry Eye
  • Eye Allergy
  • Glaucoma
  • Cataract
  • Eye Infection
  • Retinal Disorders
  • Uveitis
  • Others

Based on Application, the market is bifurcated into Dry Eye, Eye Allergy, Glaucoma, Cataract, Eye Infection, Retinal Disorders, Uveitis, and Others. The retinal disorders segment is expected to hold the largest revenue share of the global market during the forecast period owing to the rise in the geriatric population, increase in the prevalence of macular degeneration, and an increase in the sale of ophthalmic drugs for the treatment of retinal disorders. However, the glaucoma segment is expected to grow significantly during the forecast period due to an increase in glaucoma prevalence, a rising need for ophthalmic drugs, and an increase in glaucoma prevention and treatment awareness.

Ophthalmology Drugs And Devices Market, By End-User

  • Hospitals
  • Medical Clinics
  • Diagnostic Centers
  • Others

Based on End-User, the market is bifurcated into Hospitals, Medical Clinics, Diagnostic Centers, and Others. The hospitals segment is expected to grow at the highest CAGR during the forecast period owing to the increasing number of patients suffering from various eye-related disorders, and rising awareness about these disorders. Additionally, the availability of various diagnostics and treatment facilities, higher purchasing power, and the presence of highly skilled eye care professionals are driving the growth of the global market in the hospitals segment.

Ophthalmology Drugs And Devices Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World
  • On the basis of Regional Analysis, The Global Ophthalmology Drugs And Devices Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. Among the regional markets, North America accounts for the largest revenue share in the Global Ophthalmology Drugs And Devices Market in 2020 and is expected to retain its dominance throughout the forecast period. The revenue growth in the North American market is mainly attributed to the increased investment in R&D activities for the development of technologically advanced medical devices and innovative drugs for the treatment of various eye-related disorders.
  • Additionally, the increasing geriatric population, rising incidence and prevalence of various eye-related disorders, rising healthcare sectors, presence of skilled eye care professionals, and wide availability of technologically advanced ophthalmology devices are the major factors that boost the Ophthalmology Drugs And Devices Market growth across the region. The market in the Asia Pacific is projected to witness expansion at a significant growth rate during the forecast period, owing to the increasing focus on the development of healthcare infrastructure and the rising prevalence of various eye-related disorders such as glaucoma and cataract in developing nations such as China, and India in this region.

Key Players

The "Global Ophthalmology Drugs And Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Carl Zeiss AG, Novartis AG, Johnson And Johnson Services, Inc., Allergan, Topcon Corporation, Nidek Co., Ltd., HAAG-STREIT GROUP, Ziemer Ophthalmic Systems, Bausch And Lomb Incorporated, Biotech, VisionCare, Inc., Akorn, Incorporated, Bayer AG, Acucela Inc., Regeneron Pharmaceuticals, Inc, Nicox, Santen Pharmaceutical Co., Ltd. and IRIDEX Corporation, Alcon Inc. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

  • In August 2020, Topcon Corporation purchased the Henson line of perimetry products, including the Henson 9000 and 7000, from the United Kingdom-based Elektron Eye Technology (EET) of Cambridge.
  • In January 2020, iCare's IC200 tonometer device was approved by the US FDA.
  • In March 2019, Alcon Inc. acquired Power Vision Inc., a privately held medical device development company based in the United States that specializes in fluid-based intraocular lens implants.
  • In August 2018, CEQUA, developed by Sun Pharmaceutical Industries Ltd., had been approved by the US FDA for the treatment of dry eye diseases.
  • In July 2018, Amring Pharmaceuticals, Inc. introduced Biolon ophthalmic viscosurgical devices for cataract surgeons in the United States.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY PRODUCT TYPE

  • 5.1 Overview
  • 5.2 Anti-allergy
  • 5.3 Anti-Vascular Endothelial Growth Factor (Anti-VEGF) agents
  • 5.4 Anti-inflammatory
  • 5.5 Anti-glaucoma
  • 5.6 Diagnostic and Monitoring Devices
  • 5.7 Surgical Devices
  • 5.8 Vision Care
  • 5.9 Others

6 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Dry Eye
  • 6.3 Eye Allergy
  • 6.4 Glaucoma
  • 6.5 Cataract
  • 6.6 Eye Infection
  • 6.7 Retinal Disorders
  • 6.8 Uveitis
  • 6.9 Others

7 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY END-USER

  • 7.1 Overview
  • 7.2 Hospitals
  • 7.3 Medical Clinics
  • 7.4 Diagnostic Centers
  • 7.5 Others

8 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Middle East and Africa
    • 8.5.2 Latin America

9 GLOBAL OPHTHALMOLOGY DRUGS AND DEVICES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Carl Zeiss AG
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Novartis AG
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Johnson And Johnson Services, Inc.
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Allergan
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Topcon Corporation
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Nidek Co., Ltd.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 HAAG-STREIT GROUP
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Ziemer Ophthalmic Systems
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Bausch And Lomb Incorporated, Biotech
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 9.10 VisionCare, Inc.
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments
  • 9.11 Akorn
    • 9.11.1 Overview
    • 9.11.2 Financial Performance
    • 9.11.3 Product Outlook
    • 9.11.4 Key Developments
  • 9.12 Incorporated
    • 9.12.1 Overview
    • 9.12.2 Financial Performance
    • 9.12.3 Product Outlook
    • 9.12.4 Key Developments
  • 9.13 Bayer AG
    • 9.13.1 Overview
    • 9.13.2 Financial Performance
    • 9.13.3 Product Outlook
    • 9.13.4 Key Developments
  • 9.14 Acucela Inc.
    • 9.14.1 Overview
    • 9.14.2 Financial Performance
    • 9.14.3 Product Outlook
    • 9.14.4 Key Developments
  • 9.15 Regeneron Pharmaceuticals, Inc
    • 9.15.1 Overview
    • 9.15.2 Financial Performance
    • 9.15.3 Product Outlook
    • 9.15.4 Key Developments
  • 9.16 Nicox
    • 9.16.1 Overview
    • 9.16.2 Financial Performance
    • 9.16.3 Product Outlook
    • 9.16.4 Key Developments
  • 9.17 Santen Pharmaceutical Co., Ltd
    • 9.17.1 Overview
    • 9.17.2 Financial Performance
    • 9.17.3 Product Outlook
    • 9.17.4 Key Developments
  • 9.18 IRIDEX Corporation
    • 9.18.1 Overview
    • 9.18.2 Financial Performance
    • 9.18.3 Product Outlook
    • 9.18.4 Key Developments
  • 9.19 Alcon Inc
    • 9.19.1 Overview
    • 9.19.2 Financial Performance
    • 9.19.3 Product Outlook
    • 9.19.4 Key Developments

11 Appendix

    • 11.1.1 Related Reports